On April 20, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that it will participate at the following conferences (Press release, Vivoryon Therapeutics, APR 20, 2022, View Source [SID1234612572]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kempen Life Sciences Conference

Date: April 21, 2022, 10:30 am CEST

Venue: Amsterdam, The Netherlands

Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

HAIB Stockpicker Summit

Date: May 11-13, 2022

Venue: Berlin, Germany

Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

H.C. Wainwright Global Investment Conference

Date: May 25, 2022, 3:30 pm EDT (9:30 pm CEST)

Venue: Miami, FL, USA

Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

A webcast of the presentation will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 30 days following the conference.

BIO International Convention

Date: June 13-16, 2022

Venue: San Diego, CA, USA

Participants: Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO of Vivoryon Therapeutics